THRB and metabolic dysfunction-associated steatohepatitis: Recently, The New England Journal of Medicine reported the results from a phase 3 multinational, double-blind, randomized, placebo-controlled trial on the employment of Resmetirom (MGL-3196), a selective liver TRβ agonist, developed for treatment of NASH, assessing the efficacy and safety in adults with confirmed diagnosis of NASH [68].